Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06197802 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Mar 1, 2025 to Apr 5, 2024
    • Study completion date: Mar 1, 2025 to Sep 1, 2025
    v3
  2. Primary completion date: Mar 1, 2024 to Mar 1, 2025
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study completion date: Dec 1, 2024 to Mar 1, 2025
    • Start date changed from estimate of Jan 10, 2024 to Dec 30, 2023
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females 18-26 Years of Age.
Trial Details
NCT Number NCT06197802
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Conditions
(from sponsor)		 Cervical Cancer, Condylomata Acuminata
Related terms Condylomata Acuminata, Uterine Cervical Neoplasms
Enrollment 392 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov